SeQure Dx, a Waltham, Mass.-based gene-editing diagnostics company, raised $17.5m in Series A funding.
The round was led by RiverVest Venture Partners and Mass General Brigham Ventures with participation from Digitalis Ventures, Casdin Capital, KdT Ventures, Bold Capital Partners and Alexandria Venture Investments.
Led by Ellen Sheets, MD, MBA, CEO, The company intends to use the funds to establish a full-service laboratory providing off-target gene-editing analysis for use in drug development, clinical trials and patient evaluation prior to therapy.
Founded on exclusive licensure of GUIDE-seq, ONE-seq and related assay technologies for detection of off-target gene-editing events were developed by J. Keith Joung, MD, PhD, the Robert B. Colvin, MD, Endowed Chair in Pathology at Massachusetts General Hospital, and his colleagues from the MGH Department of Pathology.
Dr. Joung is a scientific founder of SeQure Dx and chair of the company’s Scientific Advisory Board. SeQure plans to expand its offerings via internal development, partnership, and further licensure.